Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.30 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534488 | 0.89 | GABRA1 (0.36) | GABRA1GABRB2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL6351804 | 0.80 | GABRA1 (0.41) | GABRA1GABRB2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL8816288 | 0.79 | TAAR1 (0.56) | KDM4ETAAR1ALDH1A1TSHRHPGD | |
| SCHEMBL6355831 | 0.79 | GABRA1 (0.38) | GABRA1GABRB2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL16954492 | 0.78 | GABRA1 (0.48) | GABRA1GABRB2TAAR1ALDH1A1TSHR | |
| SCHEMBL27583 | 0.78 | GABRA1 (0.43) | GABRA1GABRB2TAAR1ALDH1A1TSHR | |
| SCHEMBL27655851 | 0.77 | HTR1A (0.36) | GABRA1GABRB2TAAR1ADRA1APTPN1 | |
| SCHEMBL6215103 | 0.76 | TSHR (0.42) | ADRA1AALDH1A1TSHRHTR1AADRA1D | |
| SCHEMBL6219249 | 0.76 | GABRA1 (0.41) | GABRA1GABRB2TAAR1ALDH1A1GPR84 | |
| SCHEMBL31719750 | 0.76 | GABRA1 (0.41) | GABRA1GABRB2TAAR1ALDH1A1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154007-A1 | New compounds | AMIN KOSRAT (SE) | 2005-07-14 | — | — | US | disclosed |
| US-6790960-B2 | Compounds | ASTRAZENECA AB (SE) | 2004-09-14 | — | — | US | disclosed |
| EP-1411056-A2 | Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for their preparation | AstraZeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030220364-A1 | New compounds | AMIN KOSRAT (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6579884-B1 | Compounds | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| EP-1105391-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011000-A2 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220364-A1 | New compounds | SLC10A2, GIPR, FABP2 | GABRA1 1299/4885GABRB2 720/4885KDM4E 4741/4885 |
| US-20050154007-A1 | New compounds | SLC10A2, GIPR, FABP6 | GABRA1 1389/4885GABRB2 687/4885KDM4E 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.